Traveller's diarrhoea vaccine - Scandinavian Biopharma

Drug Profile

Traveller's diarrhoea vaccine - Scandinavian Biopharma

Alternative Names: Enterotoxigenic Escherichia coli vaccine - Scandinavian Biopharma; Etvax

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Scandinavian Biopharma
  • Developer PATH; Scandinavian Biopharma
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Traveller's diarrhoea

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Traveller's-diarrhoea(Prevention, In volunteers) in Sweden (PO)
  • 01 Oct 2015 Phase-I/II clinical trials in Traveller's diarrhoea (In adolescents, In adults, In children, In infants, In volunteers) in Bangladesh (PO)
  • 31 Jul 2012 Phase-I clinical trials in Traveller's diarrhoea (healthy volunteers) in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top